Organic compounds
Compounds of formula (I), which are 14-O-{[(optionally substituted hydroxy)cyclohexyl)sulfanyl]acetyl}mutilins further substituted at the cyclohexyl group by an acylated amino group, salts and solvates thereof, pharmaceutical compositions comprising such compounds and their use as a pharmaceutical, e.g. for the treatment of diseases mediated by microbes and for the treatment of inflammation where microbes are mediating said inflammation.
1. A compound of formula I
wherein
R is ethyl or vinyl;
R 1 is a group of formula
R 2 is OH or OR 1 ; and
R 3 is hydrogen, straight chain or branched (C 1-8 )alkyl or (C 3-8 )cycloalkyl, or
is that part of an natural amino acid in D or in L form which remains if the carboxylic acid group is split off, or
is that part of an non natural amino acid in D or in L form which remains if the carboxylic acid group is split off.
2. A compound according to claim 1 , wherein R is vinyl.
3. A compound according to claim 1 of formula I PREF1
4. A compound according to claim 1 of formula I PREF2
5. A compound according to claim 1 , wherein R 2 is hydroxy.
6. A compound according to claim 1 , wherein R 3 is hydrogen,
(C 3-6 )cycloalkyl, aliphatic or aromatic heterocyclyl comprising 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O and or S, with the proviso that at least one heteroatom is N, or straight chain or branched (C 1-6 )alkyl, wherein alkyl is unsubstituted or substituted by amino and optionally further substituted by
hydroxy, guanidino, aminocarbonyl, carboxy, mercapto, (C 1-4 )alkylmercapto, phenyl, hydroxyphenyl, seleno, amino, which amino optionally is substituted by heterocyclylcarbonyl, wherein heterocyclyl includes aromatic and aliphatic heterocyclyl 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O and/or S; or
aromatic or aliphatic heterocyclyl, comprising 5 to 6 ring members and comprising 1 to 4 heteroatoms selected from N, O and/or S, which heterocyclyl optionally is fused with phenyl.
7. A compound according to claim 6 , wherein R 3 is hydrogen, (C 3-6 )cycloalkyl, aliphatic heterocyclyl comprising 5 or 6 ring members and at least one nitrogen atom, or straight chain or branched (C 1-6 )alkyl substituted by amino and optionally further substituted by hydroxy.
8. A compound according to claim 1 , selected from the group consisting of:
14-O-{[(1S,2S,4S)-4-((R)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,4R)-4-((R)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,4S)-4-((S)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,4R)-4-((S)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,4S)-4-((R)-2-Amino-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,4R)-4-((R)-2-Amino-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,4S)-4-((S)-2-Amino-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,4R)-4-((R)-2-Amino-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,4S)-2-Hydroxy-4-[((R)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,4R)-2-Hydroxy-4-[((R)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,4S)-2-Hydroxy-4-[((S)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,4R)-2-Hydroxy-4-[((S)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,4S)-4-((R)-2-Amino-3-hydroxy-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,4R) diastereomer thereof,
14-O-{[(1S,2S,5R)-5-((R)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,5S)-5-((R)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,5R)-5-((S)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,5S)-5-((S)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,5R)-5-((S)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-19,20-dihydro-mutilin,
14-O-{[(1R,2R,5S)-5-((S)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-19,20-dihydro-mutilin,
14-O-{[(1S,2S,5R)-5-((R)-2-Amino-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,5S)-5-((R)-2-Amino-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,5R)-5-((S)-2-Amino-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,5S) diastereomer thereof,
14-O-{[(1S,2S,5R)-2-Hydroxy-5-[((R)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,5S)-2-Hydroxy-5-[((R)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,5R)-2-Hydroxy-5-[((R)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-19,20-dihydro-mutilin,
14-O-{[(1R,2R,5S)-2-Hydroxy-5-[((R)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-19,20-dihydro-mutilin,
14-O-{[(1S,2S,5R)-2-Hydroxy-5-[((S)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,5S)-2-Hydroxy-5-[((S)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,5R)-2-Hydroxy-5-[((S)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-19,20-dihydro-mutilin,
14-O-{[(1R,2R,5S)-2-Hydroxy-5-[((S)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-19,20-dihydro-mutilin,
14-O-{[(1S,2S,5R)-5-((R)-2-Amino-3-hydroxy-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,5S)-5-((R)-2-Amino-3-hydroxy-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,5R)-5-((S)-2-Amino-3-hydroxy-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,5S) diastereomer thereof,
14-O-{[(1S,2S,5S)-5-((R)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,5R)-5-((R)-2-Amino-3-methyl-butyrylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,5S)-5-((R)-2-Amino-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,5R)-5-((R)-2-Amino-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,5S)-2-Hydroxy-5-[((R)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1R,2R,5R)-2-Hydroxy-5-[((R)-piperidine-2-carbonyl)-amino]-cyclohexylsulfanyl]-acetyl}-mutilin,
14-O-{[(1S,2S,5S)-5-((R)-2-Amino-3-hydroxy-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,5R) diastereomer thereof,
14-O-[((1S,2S,4S)-4-Formylamino-2-hydroxy-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,4R) diastereomer thereof,
14-O—[((1S,2S,4S)-4-Acetylamino-2-hydroxy-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,4R) diastereomer thereof,
14-O—[((1S,2S,4S)-2-Hydroxy-4-isobutyrylamino-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,4R) diastereomer thereof,
14-O-{[(1S,2S,4S)-4-(2,2-Dimethyl-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,4R) diastereomer thereof,
14-O-{[(1S,2S,4S)-4-(Cyclopropanecarbonyl-amino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,4R) diastereomer thereof,
14-O—[((1S,2S,5R)-5-Formylamino-2-hydroxy-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,5S) diastereomer thereof,
14-O—[((1S,2S,5R)-5-Formylamino-2-formyloxy-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,5S) diastereomer thereof,
14-O—[((1S,2S,5R)-5-Acetylamino-2-hydroxy-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,5S) diastereomer thereof,
14-O—[((1S,2S,5R)-2-Acetoxy-5-acetylamino-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,5S) diastereomer thereof,
14-O—[((1S,2S,5R)-2-Hydroxy-5-isobutyrylamino-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,5S) diastereomer thereof,
14-O-{[(1S,2S,5R)-5-(2,2-Dimethyl-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,5S) diastereomer thereof,
14-O-{[(1S,2S,5R)-5-(Cyclopropanecarbonyl-amino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,5S) diastereomer thereof,
14-O—[((1S,2S,5S)-5-Formylamino-2-hydroxy-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,5R) diastereomer thereof,
14-O—[((1S,2S,5S)-5-Acetylamino-2-hydroxy-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,5R) diastereomer thereof,
14-O—[((1S,2S,5S)-2-Hydroxy-5-isobutyrylamino-cyclohexylsulfanyl)-acetyl]-mutilin and the (1R,2R,5R) diastereomer thereof,
14-O-{[(1S,2S,5S)-5-(2,2-Dimethyl-propionylamino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,5R) diastereomer thereof, and
14-O-{[(1S,2S,5S)-5-(Cyclopropanecarbonyl-amino)-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin and the (1R,2R,5R) diastereomer thereof.
9. A compound selected from the group consisting of:
14-O-{[(2-hydroxy-, 2-formyloxy- or 2-acetoxy-cyclohexylsulfanyl]-acetyl}-mutilins which are further substituted at the cyclohexyl group by an acylated amino group.
10. A compound according to claim 1 in the form of a salt.
11. A compound according to claim 1 for use as a pharmaceutical.
12. A pharmaceutical composition comprising a compound of claim 1 in association with at least one pharmaceutical excipient, optionally comprising one or more other pharmaceutically active agents.
13. A method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of a compound of claim 1 , optionally in combination with one or more other pharmaceutically active agents.